1 – 15 of 25
- show: 15
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2020
-
Mark
p53 is associated with high-risk and pinpoints TP53 missense mutations in mantle cell lymphoma
(
- Contribution to journal › Article
- 2017
-
Mark
Nålbiopsi är inte bästa metod för att diagnostisera lymfom : Den ökade användningen kan ge allvarliga konsekvenser för diagnostik, forskning och behandlingsutveckling
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years
(
- Contribution to journal › Article
- 2016
-
Mark
Lenalidomide-bendamustine-rituximab in untreated mantle cell lymphoma > 65 years, the Nordic Lymphoma Group phase I+II trial NLG-MCL4
(
- Contribution to journal › Article
-
Mark
15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2) : Prolonged remissions without survival plateau
(
- Contribution to journal › Article
- 2015
-
Mark
miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator.
(
- Contribution to journal › Article
- 2014
-
Mark
SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma - a Nordic Lymphoma Group study.
(
- Contribution to journal › Article
-
Mark
Nordic MCL3 study: Y-90-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma
(
- Contribution to journal › Article
- 2012
-
Mark
Upfront Autologuos Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01.
(
- Contribution to journal › Article
-
Mark
Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC plus autologous stem-cell support: still very long survival but late relapses do occur
(
- Contribution to journal › Article
- 2011
-
Mark
T Cells in Tumors and Blood Predict Outcome in Follicular Lymphoma Treated with Rituximab
(
- Contribution to journal › Article
-
Mark
Minimal residual disease assessment in childhood acute lymphoblastic leukaemia: a Swedish multi-centre study comparing real-time polymerase chain reaction and multicolour flow cytometry.
(
- Contribution to journal › Article
- 2010
-
Mark
Identification of uniquely expressed transcription factors in highly purified B-cell lymphoma samples.
(
- Contribution to journal › Article
-
Mark
Applicability of IG/TCR gene rearrangements as targets for minimal residual disease assessment in a population-based cohort of Swedish childhood acute lymphoblastic leukaemia diagnosed 2002-2006
(
- Contribution to journal › Article
-
Mark
R CHOEP 14 x 6 Followed by Systemic CNS Prophylaxis for Diffuse Large B Cell Lymphoma/Follicular Lymphoma Grade 3 with Age Adjusted IPI Score 2-3 Final Results of a Nordic Lymphoma Group Phase 2 Study Including 156 Patients Aged 18-65 Years
(
- Contribution to journal › Published meeting abstract